{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:40:30Z","timestamp":1792629630031,"version":"4.5.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2023-146827OB-I00"],"award-info":[{"award-number":["PID2023-146827OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RYC2020-029098-I"],"award-info":[{"award-number":["RYC2020-029098-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDJP2024-20"],"award-info":[{"award-number":["RDJP2024-20"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/00526"],"award-info":[{"award-number":["PI24\/00526"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["FORT23\/00034"],"award-info":[{"award-number":["FORT23\/00034"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ctrv.2025.103041","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T22:30:44Z","timestamp":1761345044000},"page":"103041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy"],"prefix":"10.1016","volume":"141","author":[{"given":"Xuesong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Castet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kreina Vega","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Saur\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanlong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian V.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103041_b0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5230\/jgc.2025.25.e11","article-title":"Korean practice guidelines for gastric cancer 2024: an evidence-based, multidisciplinary approach (Update of 2022 Guideline)","volume":"25","author":"Kim","year":"2025","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.ctrv.2025.103041_b0025","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1-25.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"10.1016\/j.ctrv.2025.103041_b0030","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Gastric Cancer 2024 [Version 5.2024:[Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10120-024-01484-8","article-title":"Adjuvant treatment for locally advanced gastric cancer: an Asian perspective","volume":"27","author":"Kim","year":"2024","journal-title":"Gastric Cancer"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103041_b0040","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/jnci\/djj393","article-title":"Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity","volume":"98","author":"Kamangar","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103041_b0045","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2015.15816","article-title":"Salt and Sodium Intake in China","volume":"315","author":"Hipgrave","year":"2016","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF01655678","article-title":"Results of gastric resection for carcinoma of the stomach: the European experience","volume":"12","author":"Heberer","year":"1988","journal-title":"World J Surg"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0055","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF01658714","article-title":"Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients","volume":"17","author":"Bonenkamp","year":"1993","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103041_b0060","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2017.01.029","article-title":"Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality","volume":"152","author":"Jun","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103041_b0065","doi-asserted-by":"crossref","first-page":"e996","DOI":"10.1016\/S2468-2667(23)00186-X","article-title":"Cancer screening in China: a steep road from evidence to implementation","volume":"8","author":"Xia","year":"2023","journal-title":"Lancet Public Health"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01671151","article-title":"Screening for gastric cancer","volume":"13","author":"Hisamichi","year":"1989","journal-title":"World J Surg"},{"key":"10.1016\/j.ctrv.2025.103041_b0075","unstructured":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-1050."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0080","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cgh.2018.05.044","article-title":"Incidence trends of esophageal and gastric cancer subtypes by race, ethnicity, and age in the United States, 1997-2014","volume":"17","author":"Islami","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7517","key":"10.1016\/j.ctrv.2025.103041_b0085","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103041_b0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrgastro.2010.154","article-title":"Mechanisms of disease: helicobacter pylori virulence factors","volume":"7","author":"Yamaoka","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103041_b0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41575-018-0069-7","article-title":"Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments","volume":"15","author":"O'Sullivan","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2025.103041_b0105","doi-asserted-by":"crossref","unstructured":"Sano T, Katai H, Sasako M, Maruyama K, editors. Gastric Lymphography and Detection of Sentinel Nodes. Lymphatic Metastasis and Sentinel Lymphonodectomy; 2000; Berlin, Heidelberg: Springer Berlin Heidelberg.","DOI":"10.1007\/978-3-642-57151-0_22"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/1097-0142(195309)6:5<987::AID-CNCR2820060518>3.0.CO;2-3","article-title":"The lymphatic spread of gastric cancer","volume":"6","author":"Sunderland","year":"1953","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.103041_b0115","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101-112.","DOI":"10.1007\/s10120-011-0041-5"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103041_b0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF02468883","article-title":"The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification","volume":"11","author":"Kajitani","year":"1981","journal-title":"Jpn J Surg"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103041_b0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18457","article-title":"Global Incidence and Mortality of Gastric Cancer, 1980-2018","volume":"4","author":"Wong","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103041_b0130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/BF01654793","article-title":"The role of lymphadenectomy in curative surgery for gastric cancer","volume":"3","author":"Soga","year":"1979","journal-title":"World J Surg"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0135","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00000658-198911000-00005","article-title":"Lymph node metastases of gastric cancer. General pattern in 1931 patients","volume":"210","author":"Maruyama","year":"1989","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archsurg.1989.01410030059010","article-title":"Is extensive lymphadenectomy necessary for surgical treatment of intramucosal carcinoma of the stomach?","volume":"124","author":"Iriyama","year":"1989","journal-title":"Arch Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02468900","article-title":"Evaluation of extended lymph node dissection for gastric cancer","volume":"2","author":"Majima","year":"1972","journal-title":"Jpn J Surg"},{"key":"10.1016\/j.ctrv.2025.103041_b0150","first-page":"316","article-title":"Technique of extended radical operation for gastric cancer","volume":"7","author":"Jinnai","year":"1962","journal-title":"Geka Chiryo"},{"key":"10.1016\/j.ctrv.2025.103041_b0155","first-page":"225","article-title":"Evaluation of extended radical operation for gastric cancer, with regard to lymph node metastasis and follow-up results","volume":"3","author":"Jinnai","year":"1968","journal-title":"Jpn J Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0160","first-page":"753","article-title":"End results of gastrectomy for gastric cancer: effect of extensive lymph node dissection","volume":"68","author":"Mine","year":"1970","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2025.103041_b0165","first-page":"249","article-title":"The long-term results of carcinoma of the stomach treated by gastrectomy, particularly the significance of the role of extended lymph node dissection","volume":"78","author":"Hara","year":"1969","journal-title":"Kyoto Furitsu Jdaishi"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0170","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/bjs.1800820321","article-title":"New method to evaluate the therapeutic value of lymph node dissection for gastric cancer","volume":"82","author":"Sasako","year":"1995","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0175","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(06)70623-4","article-title":"Nodal dissection for patients with gastric cancer: a randomised controlled trial","volume":"7","author":"Wu","year":"2006","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0180","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJMoa0707035","article-title":"D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer","volume":"359","author":"Sasako","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103041_b0185","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113-123.","DOI":"10.1007\/s10120-011-0042-4"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103041_b0190","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/archsurg.1984.01390210063014","article-title":"Lymph node metastases. Indicators, but not governors of survival","volume":"119","author":"Cady","year":"1984","journal-title":"Arch Surg"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/BF01655804","article-title":"Progress in gastric cancer surgery in Japan and its limits of radicality","volume":"11","author":"Maruyama","year":"1987","journal-title":"World J Surg"},{"issue":"9007","key":"10.1016\/j.ctrv.2025.103041_b0200","first-page":"995","article-title":"Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial","volume":"347","author":"Cuschieri","year":"1996","journal-title":"Surg Cooperative Group Lancet"},{"issue":"9\u201310","key":"10.1016\/j.ctrv.2025.103041_b0205","first-page":"1522","article-title":"Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial","volume":"79","author":"Cuschieri","year":"1999","journal-title":"Surgical Co-operative Group Br J Cancer"},{"issue":"8952","key":"10.1016\/j.ctrv.2025.103041_b0210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0140-6736(95)90637-1","article-title":"Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients","volume":"345","author":"Bonenkamp","year":"1995","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103041_b0215","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJM199903253401202","article-title":"Extended lymph-node dissection for gastric cancer","volume":"340","author":"Bonenkamp","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","article-title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial","volume":"11","author":"Songun","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejso.2003.11.020","article-title":"Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial","volume":"30","author":"Degiuli","year":"2004","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103041_b0230","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/SLA.0000000000001814","article-title":"Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma","volume":"265","author":"Sano","year":"2017","journal-title":"Ann Surg"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2025.103041_b0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS479","article-title":"Single-arm phase II trial to evaluate the safety of laparoscopic\/robotic total gastrectomy with spleen-preserving splenic hilar dissection for locally advanced proximal gastric cancer that invades the greater curvature: JCOG1809","volume":"41","author":"Kinoshita","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0240","doi-asserted-by":"crossref","first-page":"531","DOI":"10.6004\/jnccn.2013.0070","article-title":"Gastric cancer, version 2.2013","volume":"11","author":"Ajani","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 5","key":"10.1016\/j.ctrv.2025.103041_b0245","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdq164","article-title":"Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Okines","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103041_b0250","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s10120-021-01257-7","article-title":"Safe implementation of robotic gastrectomy for gastric cancer under the requirements for universal health insurance coverage: a retrospective cohort study using a nationwide registry database in Japan","volume":"25","author":"Suda","year":"2022","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103041_b0255","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/bjs\/znad065","article-title":"Diagnosis and treatment for gastro-oesophageal cancer in England and Wales: analysis of the National Oesophago-Gastric Cancer Audit (NOGCA) database 2012-2020","volume":"110","author":"Pucher","year":"2023","journal-title":"Br J Surg"},{"issue":"28","key":"10.1016\/j.ctrv.2025.103041_b0260","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1200\/JCO.20.01210","article-title":"Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial","volume":"38","author":"Hyung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103041_b0265","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1001\/jama.2019.5359","article-title":"Effect of laparoscopic vs open distal gastrectomy on 3-Year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial","volume":"321","author":"Yu","year":"2019","journal-title":"J Am Med Assoc"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103041_b0270","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.20.01540","article-title":"Laparoscopic versus open gastrectomy for gastric cancer (LOGICA): a multicenter randomized clinical trial","volume":"39","author":"van der Veen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103041_b0275","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1200\/JCO.1984.2.12.1366","article-title":"Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer","volume":"2","author":"Nakajima","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0280","first-page":"27","article-title":"Meta-analysis of adjuvant chemotherapy trials for gastric cancer at the Cancer Institute Hospital, Tokyo. Multimodality Therapy for Gastric Cancer: Appendix: Database of the Cancer Institute","author":"Nakajima","year":"1999","journal-title":"Hospital"},{"key":"10.1016\/j.ctrv.2025.103041_b0285","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-007-0415-x","article-title":"Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients","volume":"60","author":"Kochi","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103041_b0290","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ctrv.2025.103041_b0295","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0300","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0305","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients","volume":"45","author":"Sch\u00fcller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9813","key":"10.1016\/j.ctrv.2025.103041_b0310","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103041_b0315","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103041_b0320","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1200\/JCO.18.01138","article-title":"Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial","volume":"37","author":"Yoshida","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0325","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10120-021-01224-2","article-title":"Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07","volume":"25","author":"Kakeji","year":"2022","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0330","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(\u2606)","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0335","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2025.103041_b0340","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0345","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"10184","key":"10.1016\/j.ctrv.2025.103041_b0350","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103041_b0355","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0360","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01658089","article-title":"An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group","volume":"7","author":"Fielding","year":"1983","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103041_b0365","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/1097-0142(19830915)52:6<1105::AID-CNCR2820520629>3.0.CO;2-Z","article-title":"Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report","volume":"52","author":"Higgins","year":"1983","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103041_b0370","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/1097-0142(19850501)55:9<1868::AID-CNCR2820550904>3.0.CO;2-B","article-title":"Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275)","volume":"55","author":"Engstrom","year":"1985","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0375","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1200\/JCO.1990.8.8.1362","article-title":"A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group","volume":"8","author":"Coombes","year":"1990","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103041_b0380","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1200\/JCO.1996.14.6.1818","article-title":"Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil","volume":"14","author":"Kelsen","year":"1996","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ctrv.2025.103041_b0385","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103041_b0390","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0395","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejca.2012.09.025","article-title":"The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)","volume":"49","author":"Al-Batran","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103041_b0400","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103041_b0405","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10294","key":"10.1016\/j.ctrv.2025.103041_b0410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103041_b0415","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0420","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0425","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103041_b0430","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0435","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3389\/fonc.2019.01320","article-title":"VESTIGE: adjuvant immunotherapy in patients with resected esophageal, gastroesophageal junction and gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and\/or R1): an open label randomized controlled phase-2-study","volume":"9","author":"Smyth","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103041_b0440","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2025.103041_b0445","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2023.41.4_suppl.358","article-title":"INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC)","volume":"41","author":"Pietrantonio","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0450","doi-asserted-by":"crossref","first-page":"S899","DOI":"10.1016\/j.annonc.2024.08.1514","article-title":"1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR\/MSI localized cancers: results of the digestive non-colorectal cancer cohorts","volume":"35","author":"Cdl","year":"2024","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103041_b0455","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1245\/s10434-023-14103-0","article-title":"Heterogeneity and adjuvant therapeutic approaches in MSI-H\/dMMR resectable gastric cancer: emerging trends in immunotherapy","volume":"30","author":"Wu","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103041_b0460","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0465","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","article-title":"LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): Interim results of the global, phase III MATTERHORN study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann Oncol"},{"issue":"3_suppl","key":"10.1016\/j.ctrv.2025.103041_b0470","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.286","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0475","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0480","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9742","key":"10.1016\/j.ctrv.2025.103041_b0485","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2025.103041_b0490","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2020.38.15_suppl.4502","article-title":"Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO","volume":"38","author":"Hofheinz","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103041_b0495","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ijc.33696","volume":"149","author":"Hofheinz","year":"2021","journal-title":"Int J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2025.103041_b0500","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1200\/JCO.2023.41.16_suppl.4057","volume":"41","author":"Wagner","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2025.103041_b0505","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA331","article-title":"EORTC-1203 GITC \u201cINNOVATION\u201d: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: overall survival results","volume":"43","author":"Wagner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0510","doi-asserted-by":"crossref","first-page":"S877","DOI":"10.1016\/j.annonc.2024.08.1466","article-title":"1400O final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G\/GEJ adenocarcinoma","volume":"35","author":"Janjigian","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0515","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/j.annonc.2023.09.1424","article-title":"1511O Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0520","first-page":"1150","article-title":"Efficacy of Ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial","volume":"8","author":"Stein","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10389","key":"10.1016\/j.ctrv.2025.103041_b0525","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0530","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103041_b0535","unstructured":"U.S. Food and Drug Administration. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma 2024 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma."},{"key":"10.1016\/j.ctrv.2025.103041_b0540","unstructured":"European Medicines Agency. Vyloy: EPAR \u2013 Assessment History: European Medicines Agency; 2024 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyloy#assessment-history."},{"issue":"11","key":"10.1016\/j.ctrv.2025.103041_b0545","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0550","doi-asserted-by":"crossref","first-page":"S1502","DOI":"10.1016\/j.annonc.2024.10.281","article-title":"263TiP TroFuse-015: a phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician's choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)","volume":"35","author":"Shitara","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0555","doi-asserted-by":"crossref","first-page":"S895","DOI":"10.1016\/j.annonc.2024.08.1505","article-title":"1439P ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric\/gastroesophageal junction adenocarcinoma (GEA): results from a phase I study","volume":"35","author":"Strickler","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103041_b0560","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0565","doi-asserted-by":"crossref","first-page":"378","DOI":"10.6004\/jnccn.2010.0030","article-title":"Gastric cancer","volume":"8","author":"Ajani","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103041_b0570","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103041_b0575","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0580","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0585","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103041_b0590","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0595","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0600","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-018-4770-2","volume":"18","author":"Slagter","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103041_b0605","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"19","key":"10.1016\/j.ctrv.2025.103041_b0610","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative Chemoradiotherapy for Resectable Gastric Cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0615","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103041_b0620","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah","year":"2020","journal-title":"Nat Commun"},{"issue":"9938","key":"10.1016\/j.ctrv.2025.103041_b0625","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0630","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0635","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","author":"Shitara","year":"2025","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2025.103041_b0640","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0645","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103041_b0650","doi-asserted-by":"crossref","first-page":"S689","DOI":"10.1016\/j.annonc.2024.08.1076","article-title":"1017P Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2\/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)","volume":"35","author":"Klempner","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0655","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/j.annonc.2024.08.676","article-title":"609O CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric\/gastroesophageal junction cancer (GC\/GEJC): a phase I study","volume":"35","author":"Xu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0660","doi-asserted-by":"crossref","first-page":"S903","DOI":"10.1016\/j.annonc.2024.08.1522","article-title":"1456P first in human phase I\/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric\/gastroesophageal junction cancer","volume":"35","author":"Liu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0665","doi-asserted-by":"crossref","first-page":"S514","DOI":"10.1016\/j.annonc.2024.08.717","article-title":"651P phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and\/or metastatic solid tumors","volume":"35","author":"Yu","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2025.103041_b0670","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2023.41.16_suppl.3016","article-title":"First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant\/refractory solid tumors","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103041_b0675","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103041_b0680","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103041_b0685","unstructured":"American Joint Committee on Cancer. AJCC Cancer Staging Manual. In: Amin MB, Edge S, Greene F, et al., editors. AJCC Cancer Staging Manual. 8th edition ed. New York, NY: Springer; 2016."},{"issue":"11","key":"10.1016\/j.ctrv.2025.103041_b0690","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert","year":"1998","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0695","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/jjco\/hyn017","article-title":"The Japanese guidelines for gastric cancer screening","volume":"38","author":"Hamashima","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103041_b0700","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/PAI.0000000000000423","article-title":"HER2 status in Gastric and Gastroesophageal Junction Cancer: results of the Large, Multinational HER-EAGLE Study","volume":"26","author":"Kim","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ctrv.2025.103041_b0705","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.annonc.2024.05.375","volume":"35","author":"Lordick","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103041_b0710","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/annonc\/mdt232","article-title":"HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance","volume":"24","author":"Sheng","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0715","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2025.103041_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10111","key":"10.1016\/j.ctrv.2025.103041_b0725","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103041_b0730","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:14:20Z","timestamp":1773310460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722500163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":146,"alternative-id":["S030573722500163X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103041","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103041"}}